Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B

Table 3

Characteristics of study participants relative to their sGDNF levels.

	Total (N = 344)	sGDNF-low (N = 192)	sGDNF-high (N = 152)	value
Steatosis, N (%)
Negative	209 (60.8)	114 (59.4)	95 (62.5)	0.556
Positive	135 (39.2)	78 (40.6)	57 (37.5)
G stage, N (%)
0-1	32 (9.3)	20 (10.4)	12 (7.9)	0.057
2	176 (51.2)	105 (54.7)	71 (46.7)
3-4	136 (39.5)	67 (34.9)	69 (45.4)
F stage, N (%)
0	26 (7.6)	17 (8.9)	9 (5.9)	0.000
1	84 (24.4)	55 (26.8)	29 (19.1)
2	133 (38.7)	80 (41.7)	53 (34.9)
3	68 (19.8)	35 (18.2)	33 (21.7)
4	33 (9.6)	5 (2.6)	28 (18.4)
Pathology staining, (%)
Masson’s trichrome staining (N = 157)	5.0 (2.2, 9.0)	3.1 (1.2, 7.0)	6.3 (3.1, 11.4)	0.001
Reticulin staining (N = 224)	2.3 (0.9, 4.5)	1.8 (0.7, 4.3)	2.9 (1.5, 5.0)	0.023

The data are expressed as median (25–75%). for trends determined through the linear-by-linear association test. Liver histopathology of patients with G0, G1, G2, G3, and G4 according to the Scheuer scoring system. G1, portal inflammation; G2, mild piecemeal necrosis; G3, moderate piecemeal necrosis; G4, severe piecemeal necrosis and bridging necrosis. METAVIR scoring system. F0, no fibrosis; F1, portal fibrosis without septa; F2, septal fibrosis (portal-portal); F3, septal fibrosis (portal-central); F4, cirrhosis.